Post by axcura AG

IMAPAC published a report on the key outsourcing trends reshaping European biopharma manufacturing. Most commentary will focus on what it means for CDMOs and sponsors. This edition looks at it from a different angle - what it means for the raw material supply chain nobody talks about. The qualification bar has moved. The trust question is now a commercial one. And the gap between what CDMOs need from their suppliers and what most suppliers are offering is widening. ➡️ Link in the first comment. #biopharma #CDMO #biologicsmanufacturing #supplychainresilience #GMP #excipients #lifesciences #Axcura